Title |
Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal—A Multicenter, Nationwide Study
|
---|---|
Published in |
Frontiers in Medicine, June 2022
|
DOI | 10.3389/fmed.2022.901817 |
Pubmed ID | |
Authors |
Ana Rita Cruz-Machado, Sofia C. Barreira, Matilde Bandeira, Marc Veldhoen, Andreia Gomes, Marta Serrano, Catarina Duarte, Maria Rato, Bruno Miguel Fernandes, Salomé Garcia, Filipe Pinheiro, Miguel Bernardes, Nathalie Madeira, Cláudia Miguel, Rita Torres, Ana Bento Silva, Jorge Pestana, Diogo Almeida, Carolina Mazeda, Filipe Cunha Santos, Patrícia Pinto, Marlene Sousa, Hugo Parente, Graça Sequeira, Maria José Santos, João Eurico Fonseca, Vasco C. Romão |
Abstract |
To identify risk factors for SARS-CoV-2 infection and for severe/critical COVID-19, and to assess the humoral response after COVID-19 in these patients. Nationwide study of adult patients with inflammatory RMDs prospectively followed in the Rheumatic Diseases Portuguese Register-Reuma.pt-during the first 6 months of the pandemic. We compared patients with COVID-19 with those who did not develop the disease and patients with mild/moderate disease with those exhibiting severe/critical COVID-19. IgG antibodies against SARS-CoV-2 were measured ≥3 months after infection and results were compared with matched controls. 162 cases of COVID-19 were registered in a total of 6,363 appointments. Patients treated with TNF inhibitors (TNFi; OR = 0.160, 95% CI 0.099-0.260, P < 0.001) and tocilizumab (OR 0.147, 95% CI 0.053-0.408, P < 0.001) had reduced odds of infection. Further, TNFi tended to be protective of severe and critical disease. Older age, major comorbidities, and rituximab were associated with an increased risk of infection and worse prognosis. Most patients with inflammatory RMDs (86.2%) developed a robust antibody response. Seroconversion was associated with symptomatic disease (OR 13.46, 95% CI 2.21-81.85, P = 0.005) and tended to be blunted by TNFi (OR 0.17, 95% CI 0.03-1.05; P = 0.057). TNFi and tocilizumab reduced the risk of infection by SARS-CoV-2. Treatment with TNFi also tended to reduce rates of severe disease and seroconversion. Older age, general comorbidities and rituximab were associated with increased risk for infection and worse prognosis, in line with previous reports. Most patients with RMDs developed a proper antibody response after COVID-19, particularly if they had symptomatic disease. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 2 | 25% |
South Africa | 1 | 13% |
Unknown | 5 | 63% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 63% |
Scientists | 3 | 38% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 37 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Doctoral Student | 10 | 27% |
Student > Bachelor | 6 | 16% |
Student > Master | 4 | 11% |
Student > Postgraduate | 4 | 11% |
Other | 3 | 8% |
Other | 5 | 14% |
Unknown | 5 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 21 | 57% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Nursing and Health Professions | 2 | 5% |
Sports and Recreations | 2 | 5% |
Agricultural and Biological Sciences | 2 | 5% |
Other | 2 | 5% |
Unknown | 6 | 16% |